Dan Erkes‘s Abstract Melanoma is the most lethal skin cancer, leading to an estimated 8,290 deaths and 100,640 new cases in 2024. Melanoma was traditionally ...

Daniel Hirschhom‘s Abstract Immunotherapy has greatly improved survival for people with melanoma, but many patients also experience harmful side effect...

Kenneth Hu‘s Abstract Immunotherapies including immune checkpoint blockade (ICB) have seen remarkable success in the clinic. Unfortunately, many patients with late-st...

Mathieu Desaunay‘s Abstract Skin cancer is one of the most common types of cancer, with melanoma being the deadliest form. In the United States, approximately 104,9...

Pietro Berico’s Abstract Prolonged sun exposure combined with other multi-factorial cues can transform skin’s melanocytes into melanoma cells characterized by uncon...

Weili Ma’s Abstract When cancer cells metastasize to the brain, the diagnosis becomes terminal. In melanoma brain metastasis, patients are only given months to live. ...

Korbinian Kropp’s Abstract A major reason that T cell-based melanoma immunotherapies can fail, either initially or after a period of treatment, is due to mutations th...

Sarwish Rafiq’s Abstract Metastatic melanoma is one of the most aggressive, and complex cancers with a 35% 5-year survival rate. Therapies using T cells that are gene...

Prashanthi Dharanipragada’s Abstract For decades, cancer initiation and progression are thought to occur gradually through small mutational changes in its DNA. After ...